SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-019911
Filing Date
2023-12-19
Accepted
2023-12-19 16:15:25
Documents
14
Period of Report
2023-12-19
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20231219x8k.htm   iXBRL 8-K 44145
2 EX-99.1 acrs-20231219xex99d1.htm EX-99.1 19746
3 GRAPHIC acrs-20231219xex99d1001.jpg GRAPHIC 13402
  Complete submission text file 0001558370-23-019911.txt   210128

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20231219.xsd EX-101.SCH 3137
5 EX-101.LAB acrs-20231219_lab.xml EX-101.LAB 15918
6 EX-101.PRE acrs-20231219_pre.xml EX-101.PRE 10225
8 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20231219x8k_htm.xml XML 4888
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 231497478
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)